一、资产减值准备的计提概况 证券代码：603387 证券简称：基蛋生物 公告编号：2025-035 基蛋生物科技股份有限公司 关于 2025 年半年度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为客观、公允、准确地反映基蛋生物科技股份有限公司（以下简称"公司"） 截至 2025 年 6 月 30 日的资产状况和 2025 年半年度的经营成果，根据《企业会 计准则》和公司会计政策相关规定，基于谨慎性原则，公司对截至 2025 年 6 月 将相关情况公告如下： 项目 确定组合的依据 本公司对单项金额在初始确认后已经发生信用减值的应收账款、其他应收款 单独确定其信用损失。 为客观、公允、准确地反映公司财务状况和经营成果，根据《企业会计准则》 和公司相关会计政策的相关规定，基于谨慎性原则，公司对截至 2025 年 6 月 30 日的各项资产进行了减值迹象的识别和测试，并根据识别和测试的结果，计提了 相关资产的减值准备。公司 2025 年 1-6 月对各项资产计提减值准备合计为 当在单项工具层面无法以合理成本 ...

Core Viewpoint - The company is actively implementing the "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan to enhance corporate governance, innovation capabilities, and investor communication while ensuring sustainable returns for investors [1][6]. Group 1: Focus on IVD Main Business and Operational Quality - The company aims to become a globally competitive biotechnology firm by focusing on the IVD sector, expanding its product lines from low-throughput to high-throughput and automated systems, covering various testing fields [1]. - The company has established eight technology platforms and has expanded its overseas market presence to 130 countries, with overseas product revenue reaching 0.73 billion, a year-on-year increase of 45.42% [1]. - The revenue from the chemical luminescence product line reached 1.50 billion, a year-on-year increase of 10.64%, accounting for 33.54% of the company's self-produced product revenue [1]. Group 2: Increased R&D Investment and Innovation Capability - The company has increased its R&D investment to 0.88 billion in the first half of 2025, representing 17.24% of its operating income, focusing on developing differentiated products based on clinical needs [2]. - As of June 30, 2025, the company holds 383 effective patents, including 57 invention patents, 296 utility model patents, and 30 design patents [2]. - The company follows a "produce one generation, research one generation, reserve one generation" strategy to enhance its R&D capabilities and product innovation [2]. Group 3: Enhanced Corporate Governance and Compliance - The company is revising its governance structure by abolishing the supervisory board and transferring its responsibilities to the audit committee, pending approval at the 2025 first extraordinary general meeting [3]. - The company emphasizes the importance of internal control effectiveness and regularly evaluates its governance structure to ensure compliance with laws and regulations [4][5]. Group 4: Strengthened Investor Communication - The company is committed to transparent information disclosure and actively engages with investors through various channels, including performance briefings and visual reports on its official platforms [4]. - The company has established a dedicated investor relations email and hotline to facilitate ongoing communication with investors [4]. Group 5: Continuous Cash Dividends and Investor Return Mechanism - The company completed a cash dividend distribution of 0.9 yuan per 10 shares on June 17, 2025, totaling approximately 45.64 million, with cumulative cash dividends and buybacks exceeding 8.51 billion since its IPO [5]. - The company plans to maintain a stable cash dividend strategy and develop reasonable profit distribution plans to reward investors [5]. Group 6: Ongoing Evaluation of Action Plan - The company will continue to advance and assess the "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan while fulfilling its information disclosure obligations [6].

Group 1 - The company plans to abolish the supervisory board and amend its Articles of Association to enhance governance structure and operational standards [1][2] - The supervisory functions will be transferred to the audit committee under the board of directors, in compliance with relevant laws and regulations [1][2] - The proposal to abolish the supervisory board will be submitted for approval at the shareholders' meeting [1] Group 2 - The company will revise the relevant clauses in its Articles of Association, including the definition of stakeholders to include employees [2][3] - The company is registered in Nanjing and operates under the unified social credit code [3][4] - The Articles of Association will serve as a legally binding document governing the rights and obligations between the company, shareholders, and management [6][11] Group 3 - The company’s business scope includes various technical services, medical device production, and sales [7][8] - The company’s shares are to be issued based on principles of fairness and equality, ensuring equal rights for all shareholders [17][18] - The company has specific provisions regarding the acquisition of its own shares, which require shareholder approval under certain conditions [24][25]

Core Viewpoint - The company, Getein Biotech, is holding an online investor presentation on September 10, 2025, to discuss its 2025 semi-annual performance and financial results, allowing for interactive communication with investors [1][2]. Group 1: Meeting Details - The investor presentation is scheduled for September 10, 2025, from 14:00 to 15:00 [2][3]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center, accessible via the website [1][2]. - The format of the meeting will be an online interactive session [2][3]. Group 2: Participation Information - Investors can submit questions from September 3, 2025, to September 9, 2025, before 16:00 through the Roadshow Center website or via the company's email [2][3]. - The presentation will include responses to commonly asked questions from investors [2][3]. Group 3: Participants - Key participants in the meeting will include the Chairman and General Manager, Su Enben, the Chief Financial Officer, Ni Wen, and the Board Secretary, Liu Cong, along with independent directors [2].

证券代码：603387 证券简称：基蛋生物 公告编号：2025-038 基蛋生物科技股份有限公司 关于聘任证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 基蛋生物科技股份有限公司（以下简称"公司"）原证券事务代表谢玉鑫先 生因工作变动，向董事会递交辞呈，提请辞去公司证券事务代表职务。谢玉鑫先 生在担任公司证券事务代表期间恪尽职守、勤勉尽责，董事会对其在任期间为公 司作出的积极贡献表示衷心的感谢！ 公司于2025年8月29日召开第四届董事会第七次会议，审议通过了《关于聘 任证券事务代表的议案》，公司董事会同意聘请王娇女士为公司证券事务代表， 协助董事会秘书履行职责。任期自本次董事会审议通过之日起至第四届董事会届 满为止。王娇女士已取得上海证券交易所董事会秘书任职培训证明，具备履行职 责所必需的专业能力，其任职资格符合《上海证券交易所股票上市规则》等相关 规定。 公司证券事务代表的联系方式如下： 电话：025-68568577 电子邮箱：IR@getein.cn 联系地址：南京市六合区沿江工业开发区博富路9号 ...

General Principles - The implementation rules for the Strategic Committee of the company are established to enhance core competitiveness, determine development planning, and improve decision-making processes [1][2] - The Strategic Committee is a specialized working body set up by the Board of Directors, responsible for researching and proposing suggestions on the company's long-term development strategy and major investment decisions [1][2] Composition of the Committee - The Strategic Committee consists of three members, including at least one independent director [3] - The chairman of the committee is the chairman of the board, who is responsible for presiding over the committee's work [3][4] Responsibilities and Authority - The main responsibilities of the Strategic Committee include researching and proposing suggestions on long-term development strategies, major investment financing plans, significant capital operations, and other major matters affecting the company's development [8] - The committee is responsible to the Board of Directors, and its proposals are submitted for board review and decision [8] Decision-Making Procedures - A working group is responsible for preparing the committee's decisions, providing relevant materials, and conducting preliminary reviews [10] - The committee holds meetings to discuss proposals from the working group and submits the results to the Board of Directors [11] Meeting Rules - The Strategic Committee must hold at least two meetings per year, with notifications sent two days in advance [12] - A meeting requires the presence of at least two-thirds of the members to be valid, and decisions must be approved by a majority [13][14] Confidentiality and Record-Keeping - Members attending meetings have confidentiality obligations and must not disclose information without authorization [21] - Meeting records must be kept, and attendees are required to sign the records [19]

Core Points - The audit committee of the company is established to enhance the decision-making function of the board and ensure effective supervision of the management [1][2] - The audit committee consists of three members, including two independent directors, with a professional accountant serving as the chairperson [2][3] - The main responsibilities of the audit committee include supervising external and internal audits, reviewing financial reports, and assessing the effectiveness of internal controls [3][5] Group 1 - The audit committee is responsible for evaluating external audit work and proposing the hiring or replacement of external audit firms [3][10] - The committee must approve financial disclosures and significant accounting changes before submission to the board [5][6] - The committee has the authority to investigate unusual business conditions and can hire external professionals for assistance if necessary [3][12] Group 2 - The audit committee meetings must be convened with at least two-thirds of the members present to make decisions [10][11] - The committee is required to maintain confidentiality regarding the matters discussed in meetings [14] - The rules governing the audit committee's operations are subject to national laws and regulations, and any conflicts will be resolved in favor of the latter [14][36]

Core Points - The implementation rules for the Nomination, Compensation, and Assessment Committee of the company aim to improve the governance structure and establish a sound system for the nomination, assessment, and compensation management of directors and senior management [1][2] - The committee is composed of independent and external directors, with independent directors holding a majority [2][3] - The committee's main responsibilities include researching selection criteria for directors and senior management, reviewing candidates, and proposing compensation policies [8][9][10] Group 1 - The committee is a specialized working body established by the board of directors and is accountable to the board [1] - The committee's term aligns with that of the board, and members can be re-elected [2] - The human resources department provides professional support and feedback on the implementation of the committee's decisions [2][3] Group 2 - The committee is responsible for proposing standards and procedures for selecting directors and senior management, as well as reviewing and recommending candidates [8][9] - The compensation and assessment committee specifically handles the formulation of assessment standards and compensation policies for directors and senior management [10][11] - The committee's proposals for director compensation must be approved by the board and submitted for shareholder review [11] Group 3 - The selection process for directors and senior management involves extensive communication and research on the company's needs [12] - The committee must conduct a thorough review of candidates' qualifications and obtain their consent before nomination [12][13] - The human resources department provides essential materials for the committee's reference, including financial and performance indicators [13][14] Group 4 - The evaluation process for directors and senior management includes self-assessment and performance evaluation based on established standards [15] - The committee meetings require a two-thirds attendance to be valid, and decisions should reflect independent opinions [15][16] - Meeting records must be kept, and confidentiality is required from all attendees [16][17]

基蛋生物科技股份有限公司 市值管理制度 基蛋生物科技股份有限公司 市值管理制度 第一章 总则 第一条 为加强基蛋生物科技股份有限公司（以下简称"公司"）市值管理， 切实推动公司投资价值提升，增强投资者回报，维护投资者利益，根据《中华人 民共和国公司法》《中华人民共和国证券法》《上市公司信息披露管理办法》《上 市公司监管指引第 10 号——市值管理》等法律法规、规范性文件和《公司章程》 等规定，制定本制度。 第二条 本制度所称市值管理，是指公司以提高公司质量为基础，为提升投 资者回报能力和水平而实施的战略管理行为。 第三条 市值管理的基本原则包括： （一）合规性原则：公司应当在严格遵守相关法律法规、规范性文件、自律 监管规则以及《公司章程》等内部规章制度的前提下开展市值管理工作。 （三）科学性原则：公司的市值管理有其规律，应当依其规律进行科学管理， 科学研判影响公司投资价值的关键性因素，以提升公司质量为基础开展市值管理 工作。 （四）常态性原则：公司的市值成长是一个持续的和动态的过程，公司将及 时关注资本市场及公司股价动态，常态化主动跟进开展市值管理工作。 （五）诚实守信原则：公司在市值管理活动中应当注重诚信、 ...

Core Viewpoint - The document outlines the selection and appointment procedures for accounting firms by the company, emphasizing the importance of maintaining shareholder interests and ensuring the quality and authenticity of financial information [1][2]. Group 1: General Principles - The company establishes a system for the selection of accounting firms to ensure compliance with relevant laws and regulations [1]. - The selection process must be approved by the audit committee, the board of directors, and ultimately the shareholders [1][2]. - Major shareholders and actual controllers are prohibited from interfering in the selection process before board and shareholder meetings [1] Group 2: Quality Requirements for Accounting Firms - Selected accounting firms must possess independent legal status and necessary qualifications as per regulatory requirements [2]. - Firms must have a solid organizational structure, internal management systems, and a good reputation without any significant regulatory penalties in the last three years [2][3]. - The evaluation of firms will consider their audit quality, professional ethics, and compliance with relevant laws [2][3]. Group 3: Selection Procedures - The audit committee is responsible for proposing the selection of accounting firms and overseeing the process [3][4]. - The selection can be conducted through competitive negotiations, public bidding, or other transparent methods [4]. - The evaluation criteria for firms will include audit fees, qualifications, past performance, and resource allocation [4][5]. Group 4: Appointment and Reappointment - The appointment of accounting firms is formalized through a business agreement after approval from the shareholders [6][7]. - The audit committee must evaluate the performance of the accounting firm annually before reappointment [7][8]. - Adjustments to audit fees can be made based on various economic factors, with specific disclosure requirements if fees decrease significantly [7][8]. Group 5: Termination and Replacement Procedures - The company must replace accounting firms under certain conditions, such as significant quality issues or failure to meet deadlines [9][10]. - The audit committee must conduct thorough investigations before recommending a replacement [9][10]. - Detailed disclosures regarding the reasons for termination and the performance of the previous firm are required [10][11]. Group 6: Supervision and Penalties - The audit committee is tasked with supervising the audit work and ensuring compliance with laws and internal policies [11][12]. - Violations by accounting firms can lead to penalties, including potential dismissal and financial liability for responsible individuals [11][12]. - The company must ensure that any significant issues with the audit firm are addressed promptly and transparently [12].